News
Celyad successfully administers CYAD-01 in first patients in SHRINK and LINK trials
Celyad publishes additional pre-clinical data in support of THINK trial
Celyad publishes additional pre-clinical data in support of THINK trial
Celyad reports promising early results at first dose level of the solid arm of the THINK trial
Celyad reports promising early results at first dose level of the solid arm of the THINK trial
Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
Celyad initiates second dose escalation in THINK trial in first US patient
Celyad initiates second dose escalation in THINK trial in first US patient
Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies
Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies
USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial
Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial
Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2 THINK Trial in Belgium
Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2 THINK Trial in Belgium
Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells